Dr Hupert is a Monash University Medical School graduate who commenced General Practice in 1980. Realising the significant potential for computers in medicine he left general practice in late 1984 to devote himself full time to managing the Group.

Mr Hall has been principal architect and developer of the core software systems. His current focus is the transition to and development of the Company's next generation RIS systems.

Mr Kempen is Chairman of Australasian Leukaemia and Lymphoma Group and Chairman of Logie- Smith Lanyon. He is also a Trustee of the Barr Family Foundation and a member of the Board of St Hilda's College Ltd, University of Melbourne. Peter has previously been Chairman of Patties Food Limited, Chairman of Danks Holdings Limited, Chairman of Ivanhoe Grammar School and Managing Partner of Ernst & Young Corporate Finance Australia. Peter was appointed a Member in the General Division of the Order of Australia (AM) in the 2018 Queen's Birthday Honours. Peter became Chairman in August 2010 before which he served as a Non-Executive Director of the Company. Peter is also Chair of the Risk committee.

Ms Williams has had worked on range of executive roles in the financial services sector including Vice President at JP Morgan as an institutional investor with responsibility for equity investments in transport, industrial companies & infrastructure. Former senior executive roles include Director Strategy & Fleet Planning in the aviation sector. Over her career she has gained experience in risk management, including technology and cybersecurity risks as well as governance of technology projects involving outsourcing, cloud hosting and offsite support. Alice has had Board roles on ASX listed companies, including Djerriwarrh Investments Limited (current), Equity Trustees Limited and Cooper Energy Limited. She is currently a Director of Defence Health Limited, Mercer Investments (Australia) Limited and has recently joined the Board of Vocus Communications Limited. In several of these organizations Alice has been a member of, or Chair, of the Audit and Risk Committee. In addition, Alice has served on a number of Government Boards, including the Foreign Investment Review Board, Port of Melbourne Corporation, Victorian Funds Management Corporation and Airservices Australia. She has several positions in not-for-profit organizations which are primarily focused on health. She will also appoint as Chair of the Risk Committee of PME effective from 01/09/2021.

Ms Shiff also holds other board positions with Healthcare I.T. Pty Ltd, Infrastructure Australia and Opera Australia and is Chair of the Government's Australia Broadband Advisory Council. Previous board roles include Chairman of the global board of BAI Communications, Vice Chairman of the Government's Export Credit Agency EFIC , and a number of venture capital backed growth stage ICT companies. Deena has served as a Group Managing Director at Telstra, where she led the Wholesale Division Group, established and led Telstra Business and founded Telstra's corporate venture capital arm, Telstra Ventures. Deena has also held various in house regulatory and legal positions and has been a Partner of the law firm Mallesons Stephen Jacques.

Mr Glenning is the fund manager of Skalata Ventures, investing in early stage companies to help them scale and grow into significant and sustainable businesses. Anthony has previously been Chairman of Cyrise Pty Ltd, an accelerator for early stage cyber security start-ups and Investment Director of Starfish Ventures and was the founder and previously the CEO of Tonic Systems and a founding Non-Executive Director of Cameron Systems. Anthony also serves on the People & Culture committee and Risk committee.

Dr Farrell is the Head of the Health Security Division of DMTC Ltd, Managing Director of AdNED Pty Ltd, non-executive director of both Ena Respiratory Pty Ltd and Alexia Oncology Pty Ltd, a member of the Walter and Eliza Hall Institute of Medical Research Board Commercialisation Committee and a member of the Independent Advisory Council of Medicines Australia. Leigh was previously Senior Vice President, Commercial of Certara USA, Inc. where he was responsible for Asia Pacific Commercial. Prior to this, he was Chairman and COO of d3 Medicine LLC, which was acquired by Certara USA, Inc. Leigh also serves on the People & Culture committee and Risk committee.

-

-

-

-

-

-